About
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
Current Value
$39.901 Year Return
Current Value
$39.901 Year Return
Key Details
Market Cap
$3.34B
P/E Ratio
-11.19
1Y Stock Return
80.97%
1Y Revenue Growth
-
Dividend Yield
0.00%
Price to Book
4.0
Strategies that include AKRO
Double maintains 1 strategies that include AKRO - Akero Therapeutics, Inc.
Medium risk
$13,000
0.03%
Health Care Sector
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
348
Stock's related to AKRO
The stocks that are correlated to AKRO - Akero Therapeutics, Inc. are LGTY, SRCE, EVER, TREE, DADA
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| 58.11% | $481.08M | +30.17% | 3.08% | |
S SRCE1st Source Corp. | 36.36% | $1.48B | +20.77% | 2.52% |
E EVEREverQuote, Inc. | 34.67% | $952.04M | +38.95% | 0.00% |
T TREELendingTree, Inc. | 33.26% | $716.16M | +31.96% | 0.00% |
D DADADada Nexus Ltd. | 32.63% | $495.01M | -6.83% | 0.00% |
U UVVUniversal Corp. | 30.88% | $1.37B | +10.59% | 5.75% |
| 30.30% | $11.26M | -36.61% | 0.00% | |
Q QNSTQuinStreet, Inc. | 30.19% | $1.02B | +5.82% | 0.00% |
| 30.13% | $392.91M | -27.76% | 0.00% | |
A AVNSAvanos Medical, Inc. | 29.51% | $667.97M | -26.37% | 0.00% |
| 28.78% | $591.03M | +0.82% | 1.68% | |
Y YELPYelp, Inc. | 28.35% | $2.50B | -6.25% | 0.00% |
| 27.65% | $6.91B | +11.67% | 3.28% | |
| 27.58% | $1.43B | -61.21% | 0.00% | |
| 27.48% | $2.00B | -29.07% | 0.00% | |
| 27.45% | $707.56M | +18.69% | 3.71% | |
| 27.37% | $2.77B | +16.49% | 4.29% | |
T TOWNTowneBank | 27.34% | $2.55B | +25.05% | 3.23% |
| 27.28% | $5.33B | +17.27% | 1.09% | |
S SCLStepan Co. | 27.22% | $1.23B | -38.12% | 3.04% |
ETF's related to AKRO
The ETFs that are correlated to AKRO - Akero Therapeutics, Inc. are CPRJ, RSPA, QQA, BTC, EFAA
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| 60.48% | $48.38M | 0.69% | |
| 58.60% | $292.67M | 0% | |
| 55.19% | $187.77M | 0% | |
| 48.14% | $3.28B | 0.15% | |
| 46.26% | $100.03M | 0% | |
| 44.10% | $32.91M | 0.69% | |
| 31.45% | $138.92M | 0.5% | |
X XBISPDR Biotech ETF | 30.99% | $4.76B | 0.35% |
| 30.87% | $588.93M | 0.39% | |
| 30.81% | $16.17B | 0.09% | |
| 30.76% | $2.65B | 0.084% | |
| 29.65% | $3.15B | 0.39% | |
| 29.34% | $37.76B | 0.09% | |
| 29.26% | $5.61B | 0.45% | |
| 28.81% | $3.89B | 0.41% | |
| 27.98% | $158.14M | 0.35% | |
| 27.48% | $651.33M | 0.36% | |
| 26.89% | $107.91M | 0.6% | |
| 26.34% | $224.98M | 0.58% | |
| 26.06% | $954.59M | 0.62% | |
News
Yahoo
Here is how Agilon Health (AGL) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.
Yahoo
We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against the other biotech stocks. No matter the market environment, you’ll always find entertainment in the biotech space. There will always be […]
Yahoo
-- Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed enrollment of the double-blinded portion of the Phase 3 SYNCHRONY Real-World Study evaluating EFX in patients with either MASLD or MASH -- -- Presented New Analyses of Week 96 Phase 2b HARMONY in Patients with Pre-Cirrhotic (F2-F3) MASH at the 75th Annual AASLD The Liver Meeting® 2024 -- SOUTH SAN FR
Yahoo
We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going to take a look at where Akero Therapeutics Inc. (NASDAQ:AKRO) stands against other best performing mid cap stocks to buy according to analysts. On February 7, Simeon Hyman, Global Investment Strategist at […]
Yahoo
We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other best performing pharma stocks so far in 2025. What’s Going on in the Pharma Sector? On February 20, Jared Holz, […]
Yahoo
We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other best performing healthcare stocks so far in 2025. The Healthcare Sector and its Dynamics in the Stock Market Despite the […]
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds